Table 1 |
|||||||
|
Composition of study cohorts |
|||||||
| Patient ID |
Cohort |
Doses received |
EOT → B× time lapse (hours) |
Histology |
ΔCD8 |
ΔCD56 |
Tumor at EOT |
|
|
|||||||
| P5 |
Imiq q12 × 2 days |
4 |
13 |
Nodular |
0 |
-1 |
+ |
| P6 |
Imiq q12 × 2 days |
4 |
14 |
Undetermined |
0 |
0 |
+ |
| P17 |
Imiq q12 × 2 days |
4 |
36 |
Undetermined |
NE |
NE |
- |
| P18 |
Imiq q12 × 2 days |
4 |
33 |
Nodular |
+1 |
0 |
+ |
| P30 |
Imiq q12 × 2 days |
4 |
16 |
Nodular |
0 |
0 |
- |
| P38 |
Imiq q12 × 2 days |
4 |
17 |
Nodular |
0 |
0 |
+ |
| P231 |
Imiq q12 × 2 days |
4 |
22 |
Undetermined |
+1 |
0 |
+ |
| P10 |
Vehic q12 × 2 days |
4 |
12 |
Nodular |
0 |
0 |
+ |
| P23 |
Vehic q12 × 2 days |
2 |
15 |
Nodular |
+2 |
0 |
+ |
| P26 |
Vehic q12 × 2 days |
4 |
45 |
Nodular |
0 |
0 |
+ |
| Mean ± SD = 22 ± 11.5 |
|||||||
| P1 |
Imiq q12 × 4 days |
8 |
8 |
Nodular |
0 |
0 |
+ |
| P21 |
Imiq q12 × 4 days |
8 |
41 |
Nodular |
0 |
+1 |
+ |
| P22 |
Imiq q12 × 4 days |
8 |
11 |
Nodular |
+1 |
0 |
- |
| P40 |
Imiq q12 × 4 days |
8 |
17 |
Nodular |
+1 |
+1 |
- |
| P42 |
Imiq q12 × 4 days |
8 |
3 |
Undetermined |
+3 |
0 |
- |
| P129 |
Imiq q12 × 4 days |
8 |
19 |
Nodular |
+1 |
0 |
+ |
| P135 |
Imiq q12 × 4 days |
8 |
21 |
Superficial |
+1 |
+1 |
- |
| P41 |
Vehic q12 × 4 days |
8 |
28 |
Nodular |
+1 |
0 |
+ |
| P134 |
Vehic q12 × 4 days |
8 |
19 |
Nodular |
+2 |
0 |
+ |
| P8 |
Vehic q12 × 4 days |
8 |
20 |
Nodular |
0 |
0 |
+ |
| P20 |
Vehic q12 × 4 days |
8 |
16 |
Superficial |
0 |
0 |
+ |
| Mean ± SD = 18 ± 10.2 |
|||||||
| P11 |
Imiq q24 × 4 days |
4 |
26 |
Nodular |
0 |
+1 |
+ |
| P28 |
Imiq q24 × 4 days |
3 |
20 |
Nodular |
NE |
NE |
+ |
| P112 |
Imiq q24 × 4 days |
4 |
44 |
Nodular |
0 |
0 |
+ |
| P214 |
Imiq q24 × 4 days |
4 |
51 |
Nodular |
+2 |
+1 |
- |
| P4 |
Vehic q24 × 4 days |
4 |
16 |
Superficial |
NE |
-1 |
- |
| P13 |
Vehic q24 × 4 days |
4 |
30 |
Nodular |
0 |
0 |
+ |
| P36 |
Vehic q24 × 4 days |
4 |
25 |
Superficial |
0 |
0 |
+ |
| Mean ± SD = 30 ± 12.8 |
|||||||
| P233 |
Imiq q24 × 8 days |
8 |
32 |
Undetermined |
0 |
+1 |
+ |
| P132 |
Imiq q24 × 8 days |
8 |
159 |
Undetermined |
0 |
+2 |
- |
| P24 |
Imiq q24 × 8 days |
8 |
48 |
Superficial |
+1 |
0 |
- |
| P3 |
Imiq q24 × 8 days |
8 |
12 |
Undetermined |
-1 |
0 |
+ |
| P2 |
Vehic q24 × 8 days |
8 |
6 |
Undetermined |
0 |
-1 |
+ |
| P15 |
Vehic q24 × 8 days |
8 |
21 |
Nodular |
0 |
0 |
+ |
| P27 |
Vehic q24 × 8 days |
8 |
26 |
Nodular |
NE |
NE |
+ |
| P137 |
Vehic q24 × 8 days |
8 |
11 |
Superficial |
0 |
0 |
+ |
| Mean ± SD = 39 ± 50.3 |
|||||||
|
|
|||||||
|
Punch biopsies are labeled according to patient number (P1 to P42) and timing of excision: PB0, pre-enrollment; PB1 and PB2, pre-treatment; PB3 and PB4, post-treatment. Biopsies from patients replacing drop-outs were labeled one digit to the serial number (that is, P101 to P142 or P201 to P242. PB1 and PB3 were collected for total RNA isolation; PB2 and PB4 for IHC. Undetermined refers to a BCC histology in-between superficial and nodular. ΔCD8 and ΔCD56 scores differences in infiltrate between EOT and pre-treatment samples (see Materials and methods). Tumor at EOT: identifiable (+) or not identifiable (-) tumor cells in the hematoxylin eosin stained EOT biopsy. Imiq, imiquimod; NE, not evaluated; Vehic, vehicle. |
|||||||
|
Panelli et al. Genome Biology 2007 8:R8 doi:10.1186/gb-2007-8-1-r8 |
|||||||